Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice

Acta Neuropsychiatrica

Volumn 26, Issue 1, 2014, Pages 29-34

  Kara, Nirit Z ^a,b   Karpel, Orit ^b   Toker, Lilach ^b   Agam, Galila ^b   Belmaker, Robert H ^b   Einat, Haim ^a,b,c  

^a ACADEMIC COLLEGE OF TEL AVIV YAFFO   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

animal models; anticonvulsants; bipolar disorder; depression; mania; mice; mood stabilisers

Indexed keywords

AMPHETAMINE; CARBAMAZEPINE;

ACUTE DRUG ADMINISTRATION; AMPHETAMINE INDUCED HYPERACTIVITY TEST; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EXPERIMENTAL DEPRESSION TEST; FOOD; FORCED SWIM TEST; IMMOBILITY; MALE; MOOD STABILIZING ACTIVITY; MOUSE; MOUSE MODEL; NONHUMAN; SPONTANEOUS ACTIVITY TEST; TAIL SUSPENSION TEST; AFFECT; ANIMAL; BLOOD; C57BL MOUSE; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; DRUG MEGADOSE; HYPERACTIVITY; MANIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; AFFECT; ANIMALS; BIPOLAR DISORDER; CARBAMAZEPINE; DEPRESSION; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MOTOR ACTIVITY;

EID: 84893742756     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2013.23     Document Type: Article

References (22)

1. BELMAKER RH. Bipolar disorder. N Engl J Med 2004; 351:476-486.
2. GOULD TD, QUIROZ JA, SINGH J, ZARATE CA, MANJI HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004;9:734-755.
3. EINAT H. Modelling facets of mania-new directions related to the notion of endophenotypes. J Psychopharmacol 2006; 20:714-722.
4. EINAT H. Different behaviors and different strains: potential new ways to model bipolar disorder. Neurosci Biobehav Rev 2007;31:850-857.
5. COX C, HARRISON-READ PE, STEINBERG H, TOMKIEWICZ M. Lithium attenuates drug-induced hyperactivity in rats. Nature 1971;232:336-338.
6. CRYNS K, SHAMIR A, SHAPIRO J et al. Lack of lithium-like behavioral and molecular effects in IMPA2 knockout mice. Neuropsychopharmacology 2007;32:881-891.
7. EINAT H, YUAN P, SZABO ST, DOGRA S, MANJI HK. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007;55:123-131.
8. GOULD TD, EINAT H. Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 2007;31:825-831.
9. O'BRIEN WT, HARPER AD, JOVE F et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004;24:6791-6798.
10. BERSUDSKY Y, SHALDUBINA A, BELMAKER RH. Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav Pharmacol 2007;18:77-80.
11. KOVACSICS CE, GOULD TD. Shock-induced aggression in mice is modified by lithium. Pharmacol Biochem Behav 2009;94:380-386.
12. ARBAN R, MARAIA G, BRACKENBOROUGH K et al. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 2005;158: 123-132.
13. KALINICHEV M, DAWSON LA. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK-3) inhibitors in a strain specific model of acute mania. Int J Neuropsychopharmacol 2011;6:1-17.
14. ELPHICK M. Effects of carbamazepine on dopamine function in rodents. Psychopharmacology (Berlin) 1989;99:532-536.
15. BARROS HM, LEITE JR. The effects of carbamazepine on two animal models of depression. Psychopharmacology (Berlin) 1987;92:340-342.
16. KITAMURA Y, AKIYAMA K, KITAGAWA K et al. Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? Pharmacol Biochem Behav 2008; 89:235-240.
17. SHALDUBINA A, EINAT H, SZECHTMAN H, SHIMON H, BELMAKER RH. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 2002;109:433-440.
18. CHEN J, CAI F, CAO J, ZHANG X, LI S. Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain. J Neurosci Res 2009;87:2898-2907.
19. SZYMCZYK G, ZEBROWSKA-LUPINA I. Influence of antiepileptics on efficacy of antidepressant drugs in forced swimming test. Pol J Pharmacol 2000;52:337-344.
20. POST RM, KETTER TA, UHDE T, BALLENGER JC. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 2007;21:47-71.
21. FOUNTOULAKIS KN, GRUNZE H, PANAGIOTIDIS P, KAPRINIS G. Treatment of bipolar depression: an update. J Affect Disord 2008;109:21-34.
22. ALI A, DUA Y, CONSTANCE JE, FRANKLIN MR, DUDEK FE. A once-per-day, drug-in-food protocol for prolonged administration of antiepileptic drugs in animal models. Epilepsia 2012;53:199-206.